Company intelligence / Profile preview

LUCA AICell

Anyang, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

LUCA AICell has developed a proprietary lipid bilayer platform enabling broad-spectrum antiviral therapies, drug delivery for mRNA and gene therapies, cancer/virus diagnostics, and gene delivery. Their work is in the preclinical stage, with ongoing collaborations and technology partnerships, but no public clinical trial results yet.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Lipid nanoparticle delivery therapySmall moleculeAntiviral peptideGene deliveryAntibody
Industry: Biotech

Drug pipeline

1 asset

Antiviral Peptide

Unknown

Partnerships

ABITEC CorporationLarodanNTU SingaporeSNU HospitalCHA BiotechUNISTHongik UniversityStanford UniversityHarvard UniversityUCLAUtrecht UniversityTwenteGhent UniversityONOM MongoliaUFMG Brazil

Beyond the preview

Go deeper on LUCA AICell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LUCA AICell.

Explore the full profile